Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection

AIM: Lamivudine (LAM) and adefovir dipivoxil (ADV) are widely used in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), but few studies have directly compared their therapeutic efficacy and treatment cost. This study aims to compare LAM with ADV head-to-head in these pati...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Onco Targets Ther
Huvudupphovsmän: Zhong, Jian-Hong, Ke, Yang, Zhu, Shao-Liang, Wang, Lin, Luo, Cheng-Piao, Gong, Wen-Feng, You, Xue-Mei, Ma, Liang, Xiang, Bang-De, Li, Le-Qun
Materialtyp: Artigo
Språk:Inglês
Publicerad: Dove Medical Press 2016
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5108611/
https://ncbi.nlm.nih.gov/pubmed/27877054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S120062
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk